Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate

Andrew B Das1, Carlos C Smith-Díaz2, Margreet C M Vissers2

  • 1Department of Pathology and Biomedical Science, University of Otago, Christchurch. andrew.das@otago.ac.nz.

Haematologica
|October 26, 2020
PubMed
Summary

Epigenetic drugs show promise for acute myeloid leukemia but face challenges like varied patient response and resistance. Ascorbate may offer a new therapeutic strategy by targeting epigenetic plasticity and restoring enzyme function.